Over the past decade, surveillance data show a sustained increase in resistance to carbapenems. PAHO calls for stronger prevention and surveillance, as well as the responsible use of antimicrobials.
Washington, D.C., November 18, 2026 (PAHO) – Resistance to antibiotics used as a last line of treatment for certain serious bacterial infections has increased steadily over the past decade in the Americas, according to data from the Pan American Health Organization (PAHO).
The increase was observed in two important bacteria and involves carbapenems, a group of antibiotics often used when other treatments are ineffective. This trend is concerning because it reduces available treatment options and makes it more difficult to care for patients with serious infections.
According to data from the Latin American and Caribbean Antimicrobial Resistance Surveillance Network (ReLAVRA+), resistance to these antibiotics in Klebsiella pneumoniae rose from approximately 15% in 2015 to 26% in 2024, while in Escherichia coli it increased from 3% to 5%. The estimates are based on data from 15 and 13 countries, respectively.
The data also show high levels of resistance in other priority pathogens. In 2024, median resistance to carbapenems in Acinetobacter baumannii reached 77% across the seven countries that reported data for this bacteria–antibiotic combination, highlighting the scale of the challenge and the need to expand surveillance.
“These data mean that hospital-acquired infections are becoming increasingly difficult to treat, posing greater risks to patients. That is why it is urgent to strengthen surveillance, prevent infections, and promote access to new, effective antibiotics, while ensuring their appropriate use to preserve their effectiveness,” said Pilar Ramón Pardo, Chief of PAHO's Special Program on Antimicrobial Resistance.
Infections caused by resistant bacteria pose a significant challenge in hospitals where they affect vulnerable patients. However, antibiotic resistance is also a problem in communities, as it can make common infections, such as urinary tract infections, more difficult to treat and increase the risk of complications and hospitalization. This underscores the importance of preventing infections and ensuring timely diagnosis and appropriate treatment both within and outside health facilities.
The findings are being presented during World Antimicrobial Resistance Awareness Week, taking place between November 18 and 24 under the theme “One Health, One Action: Act Now to Prevent AMR.” The campaign aims to raise awareness of antimicrobial resistance (AMR), which occurs when bacteria, viruses, fungi, and parasites no longer respond to the medicines used to treat them, and to promote coordinated action to address this threat across human, animal, and environmental health.
To address AMR, PAHO works with countries across the Americas to strengthen surveillance systems, laboratory capacities, and the timely detection of resistant microorganisms. Through ReLAVRA+, the Organization supports the generation and analysis of data to identify resistance trends and inform public health decisions. It also promotes infection prevention and control, as well as access to and responsible use of antimicrobials.
Antimicrobial resistance also poses a challenge to animal health and food safety. The use of antimicrobials in animals can contribute to the development of resistant bacteria, which can be transmitted to people through food, contact with animals, or the environment. PAHO therefore works through its Pan American Center for Foot-and-Mouth Disease and Veterinary Public Health (PANAFTOSA), a key player in implementing the One Health approach in the region, to promote resistance surveillance and collaboration among the human, animal, and environmental health sectors.
“Resistant bacteria can circulate among animals, food, people, and the environment. That is why it is essential for countries to share information and strengthen their surveillance systems to detect these risks early and prevent their spread,” said Manuel Sánchez Vázquez, Director of PAHO's PANAFTOSA.
These efforts are part of the new Plan of Action on Antimicrobial Resistance 2027–2031, approved by PAHO Member States during the 63rd Directing Council in September 2026. The plan aims to strengthen the regional response through greater coordination across sectors, improved surveillance and laboratory capacities, infection prevention, and the promotion of appropriate antimicrobial use, with the goal of preserving the effectiveness of these essential medicines and protecting population health.
